Board meetings, strategic plans, and buyer signals from Patrick D. Wortmann’s organization
Jun 12, 2026·StrategicPlan
Board
University Of Nebraska Medical Center Strategic Goals 2027-2030
This document outlines the University of Nebraska Medical Center's strategic goals for the period of 2027-2030, which will be reviewed annually. The plan focuses on key areas including extraordinary teaching and learning, fostering research and creative activity, enhancing partnerships and engagement, cultivating a positive culture and environment, ensuring stewardship and effectiveness, and improving clinical care in partnership with Nebraska Medicine. The goals aim to advance education, research, clinical practice, and community impact, while supporting faculty, staff, and students.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The meeting included the acceptance of the previous month's minutes. Key discussion centered on the review of initial research proposals and continuing research protocols. One initial protocol (IBC#: 25-10-023-ABL1) was conditionally approved, pending an update to lab room numbers. Several continuing reviews were conducted: one protocol was conditionally approved requiring updates regarding post-treatment sample collection and cryopreservation room numbers; another was conditionally approved requiring revisions to the description of laboratory work associated with the vaccine; and others were approved or conditionally approved pending personnel or documentation updates. One protocol (IBC#: 14-11-025-EX) was approved without recommendation.
Nov 13, 2025·BoardMeeting
Board
Institutional Biosafety Committee Meeting Minutes
The Institutional Biosafety Committee (IBC) meeting addressed several research protocols. Key discussion points included a policy change to remove protocols from the 'problem child' 1-year review list after completing continuing review submissions. For protocol IBC#: 25-10-023-ABL1, involving the use of AAV constructs in mice to study anxiety, the committee decided to table the motion pending review of the associated IACUC protocol. Protocol IBC#: 25-10-024-BL2, concerning environmental sampling for bacteria and fungi, was conditionally approved pending a laboratory inspection and specific procedural updates. Several change requests were reviewed, including adding replication-defective rabies viral vector use (IBC#: 08-07-017-ABL2) and adding BALB/c mice and coxsackievirus B3 injection (IBC#: 25-07-017-ABL2), both of which were conditionally approved pending modifications and training completion. One protocol (IBC#: 18-01-001-ABL2) was noted as lengthy and was conditionally approved with instructions to split the project into two new protocols. Continuing reviews for protocols involving influenza virus characterization (IBC#: 24-11-036-BL2) and HSV/HIV countermeasures testing (IBC#: 24-11-041-BL2) were approved. Another protocol (IBC#: 24-11-039-ABL2) concerning Cre-mediated recombination in neuroendocrine cells was conditionally approved pending a laboratory inspection. Protocol (IBC#: 22-09-027-BL2) regarding CAR-T cell therapy was tabled to allow for minor Section I changes and clarification on sample processing.
The Institutional Biosafety Committee (IBC) meeting included discussions and decisions on various research proposals and protocol changes. The committee reviewed and approved initial research proposals involving CAR-T cell therapy for lymphoma, a vaccine for non-small-cell lung cancer, and an expanded access program for acute lymphoblastic leukemia. Additionally, a porcine model of pancreatic cancer was discussed, and changes to a protocol involving antimicrobial peptides were reviewed. The committee also conducted continuing reviews of active research protocols, addressing topics such as virulence factors for Coxiella burnetii and clinical trials for B-cell malignancies.
Extracted from official board minutes, strategic plans, and video transcripts.
